In May 2024, Google DeepMind released AlphaFold 3, a game changing protein folding model that predicts with 50% better ...

A daily pill, Kisqali is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor that prevents cancer cells from dividing and growing. This kind of drug is taken with an aromatase inhibitor ...

coming in at 90.4% for Kisqali and 87.1% for endocrine therapy, but represented a significant improvement for Novartis’ drug, according to lead investigator Dennis Slamon of UCLA Jonsson ...

Ribociclib belongs to a class of medications called kinase inhibitors; it inhibits the cyclin-dependent kinase (CDK) 4 and 6. It is used for treating hormone receptor (HR)-positive, human ...

Medications are the mainstay of treatment for multiple sclerosis (MS). Many of them are used to block the immune system's attack on the nerves and slow or prevent progression and relapses (flare-ups) ...

Using this approach revealed a drug resistance feedback loop in high-grade serous ovarian cancer, suggesting that combining phosphatidylinositol 3-OH kinase, protein kinase B and mammalian target ...

For some woman with HER2 positive metastatic breast cancer, the drug ENHERTU could be a game changer. Early results from a recent study released at a European oncological conference show that ENHERTU ...

At close: November 8 at 3:00 PM EST ...

In a report, Philippine National Police-Drug Enforcement Group (PDEG) chief Brig. Gen. Eleazar Matta said… Read More ...

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 153,500 newsletter subscribers for 21 days.